FDA approves denosumab biosimilar Degevma (Xgeva biosimilar)
FDA approval · Renal & Urology News · 2026-10-03. Number 3 in the UrologyWatch Top 5 for October 5, 2026.
The FDA approved Teva's denosumab biosimilar Degevma, referencing Xgeva, expanding options for skeletal-related event prevention in advanced genitourinary cancers with bone metastases.
Why it matters: Biosimilar approval may affect cost and access for bone-targeted therapy in men with bone-metastatic prostate cancer.
Source: Renal & Urology News
Loading today's edition…